Screener
Jazz Pharmaceuticals JAZZ Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther.
The source filing: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026.
- Filed
- Feb 24, 2026, 4:10 PM EST
- Fiscal year
- FY2028
- Accession
- 0001232524-26-000013
| Line item | Year Ended December 31, | Year Ended December 31, | Year Ended December 31, |
|---|---|---|---|
| Effects of cross-border tax laws(1) | 29,812 | (4.7) | |
| Non-taxable/non-deductible items | |||
| Non-deductible financing costs | 7,070 | (1.1) | |
| Other | 963 | (0.2) | |
| Foreign tax effects | |||
| United States | |||
| Statutory income tax rate differential | (74,137) | 11.8 | |
| Non-deductible acquired in-process research and development expense | 187,346 | (29.8) |
Item 16. Form 10-K Summary
FAQ
- What is Jazz Pharmaceuticals's other operating expenses?
- Jazz Pharmaceuticals (JAZZ) reported other operating expenses of -0.2% in Q4 2025.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Jazz Pharmaceuticals's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude